hydroxygenkwanin and Lung-Neoplasms

Epidermal growth factor receptor (EGFR) is frequently overexpressed and mutated in non-small cell lung cancer (NSCLC), which is the major type of lung cancer. The EGFR tyrosine kinase inhibitors (TKIs) are the approved treatment for patients harboring activating mutations in the EGFR kinase. However, most of the patients treated with EGFR-TKIs developed resistance. Therefore, the development of compounds exhibiting unique antitumor activities might help to improve the management of NSCLC patients. The total flavonoids from

Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Cell Survival; Daphne; ErbB Receptors; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Proteins; Proteolysis; Signal Transduction; Transcriptome